However, with the application of ICIs among patients with cervical cancer, some preliminary findings have shown the efficacy and safety of PD-1/PD-L1 inhibitors in selected patients, suggesting that PD-L1 expression might be one of the prognostic factors for the efficacy of immunotherapy. Here, CD274 is linked to cervical cancer.